{"title":"CD5-positive, Small B-Cell Lymphoproliferative Disorders: Aberrant Findings of CLL/SLL and MCL","authors":"Youjun Hu, M. Golightly","doi":"10.7156/V3I4P181","DOIUrl":null,"url":null,"abstract":"Most common CD5-positive, small B cell lymphoproliferative disorders include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Among these cases, atypical morphology, immunophenotype, and/or cytogenetic abnormalities are not uncommon. As an aberrant marker, CD5 expression is not limited to the cells of CLL/SLL or MCL and has been found in other B cell lymphomas ( both low grade and more aggressive types). CD5-negative CLL/SLL and MCL also are well documented, as are reports of other aberrant immunophenotypes of CLL/SLL and MCL. In addition, monoclonal B-cell lymphocytosis (MBL) of unknown significance has recently been reported in otherwise healthy individuals. We review here the findings that do not fulfill the current definitions of CLL/SLL or MCL. It is imperative that a pathologist should be familiar with these aberrant findings when considering CLL/SLL or MCL as a possible diagnosis. Furthermore, these aberrant findings may be clues to further understanding these entities .","PeriodicalId":19338,"journal":{"name":"North American journal of medicine & science","volume":"32 1","pages":"181"},"PeriodicalIF":0.0000,"publicationDate":"2010-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"North American journal of medicine & science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7156/V3I4P181","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Most common CD5-positive, small B cell lymphoproliferative disorders include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Among these cases, atypical morphology, immunophenotype, and/or cytogenetic abnormalities are not uncommon. As an aberrant marker, CD5 expression is not limited to the cells of CLL/SLL or MCL and has been found in other B cell lymphomas ( both low grade and more aggressive types). CD5-negative CLL/SLL and MCL also are well documented, as are reports of other aberrant immunophenotypes of CLL/SLL and MCL. In addition, monoclonal B-cell lymphocytosis (MBL) of unknown significance has recently been reported in otherwise healthy individuals. We review here the findings that do not fulfill the current definitions of CLL/SLL or MCL. It is imperative that a pathologist should be familiar with these aberrant findings when considering CLL/SLL or MCL as a possible diagnosis. Furthermore, these aberrant findings may be clues to further understanding these entities .